Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of Bone Biologics Corp (NASDAQ: BBLG) was $1.42 for the day, up 1.07% from the previous closing price of $1.4. In other words, the price has increased by $1.07 from its previous closing price. On the day, 72793.0 shares were traded. BBLG stock price reached its highest trading level at $1.577 during the session, while it also had its lowest trading level at $1.42.
Ratios:
Our analysis of BBLG’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 19.00 and its Current Ratio is at 19.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBLG now has a Market Capitalization of 2549269 and an Enterprise Value of -3499814.
Stock Price History:
The Beta on a monthly basis for BBLG is 0.79, which has changed by -0.8080601 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, BBLG has reached a high of $8.16, while it has fallen to a 52-week low of $1.30. The 50-Day Moving Average of the stock is -33.29%, while the 200-Day Moving Average is calculated to be -60.07%.
Shares Statistics:
BBLG traded an average of 1.98M shares per day over the past three months and 42020 shares per day over the past ten days. A total of 1.80M shares are outstanding, with a floating share count of 1.79M. Insiders hold about 0.04% of the company’s shares, while institutions hold 0.73% stake in the company. Shares short for BBLG as of 1763078400 were 24812 with a Short Ratio of 0.01, compared to 1760486400 on 54813. Therefore, it implies a Short% of Shares Outstanding of 24812 and a Short% of Float of 1.38.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. Analysts are recommending an EPS of between -$2.36 and -$2.36 for the fiscal current year, implying an average EPS of -$2.36. EPS for the following year is -$1.36, with 1.0 analysts recommending between -$1.36 and -$1.36.
